Edobacomab
| Autor: | Donna McTavish, Malini Haria |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Drug
Necrosis Lipopolysaccharide business.industry media_common.quotation_subject medicine.disease Edobacomab Sepsis Lipid A chemistry.chemical_compound chemistry In vivo Immunology medicine Immunology and Allergy Pharmacology (medical) Animal studies medicine.symptom business medicine.drug media_common |
| Zdroj: | Clinical Immunotherapeutics. 6:413-419 |
| ISSN: | 1172-7039 |
| DOI: | 10.1007/bf03259360 |
| Popis: | ▲ Edobacomab is a murine monoclonal antibody (IgM) directed against the lipid A moiety of endotoxin from Gram-negative bacteria. ▲ Edobacomab reduces circulating levels of endotoxin [lipopolysaccharide (LPS)] and tumour necrosis factor in vivo. ▲ Animal studies have shown that edobacomab improves survival and protects against the haemodyna-mic consequences of LPS challenge. ▲ Data from an early phase III clinical study suggested that edobacomab may improve survival in patients with Gram-negative sepsis who are not in refractory shock. These results were, however, not substantiated in a later study. The drug appears to enhance resolution of organ failure in patients with Gram-negative infection. ▲ Approximately 40 to 50% of patients may develop delayed antimurine antibody responses after administration of edobacomab. These have not been associated with clinical symptoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|